BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 8, 2006, Pages 1123-1125

  Chang, Chung Che ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; ERYTHROPOIETIN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; JANUS KINASE 2; STAT PROTEIN; THROMBOPOIETIN RECEPTOR;

CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC ACCURACY; ERYTHROCYTOSIS; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; PROGNOSIS; SHORT SURVEY; THROMBOCYTHEMIA; THROMBOCYTOSIS;

BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL PROLIFERATION; GENES, ABL; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PORTRAITS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; SIGNAL TRANSDUCTION;

EID: 33746661622     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80:1220-1232.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434: 1144-1148.
3. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology. 2005:195-200.
4. Tefferi A, Pardanani A. Mutation screening for JAK2(V617F): when to order the test and how to interpret the results. Leuk Res. 2006;30:739-744.
5. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma. 2006;47:177-194.
6. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
7. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G> is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
8. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106: 3377-3379.
9. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25:1434-1436.
10. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-18967.
11. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol. 2006;13:93-98.
12. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006; 107:2098-2100.
13. V617F mutation in myeloproliferative disorders by melting curve analysis using the Light-Cycler system. Arch Pathol Lab Med. 2006;130: 997-1003.